Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status

Neuro-Oncology

Volumn 16, Issue 6, 2014, Pages 779-786

  Baldock, Anne L ^a   Yagle, Kevin ^b   Born, Donald E ^c   Ahn, Sunyoung ^b   Trister, Andrew D ^b   Neal, Maxwell ^b   Johnston, Sandra K ^b   Bridge, Carly A ^a   Basanta, David ^a,d   Scott, Jacob ^a,d   Malone, Hani ^e   Sonabend, Adam M ^e   Canoll, Peter ^f   Mrugala, MacIej M ^b   Rockhill, Jason K ^a,b   Rockne, Russell C ^a,g   Swanson, Kristin R ^a,g,h  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h Northwestern University   (United States)

Author keywords

glioma; growth kinetics; IDH1; invasion; mathematical model; patient specific; proliferation

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

AGGRESSIVENESS; AREA UNDER THE CURVE; ARTICLE; CELL DENSITY; CONTRAST ENHANCEMENT; GENE MUTATION; GLIOBLASTOMA; GLIOMA CELL; GROWTH RATE; HISTOLOGY; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; BRAIN TUMOR; GENETICS; MUTATION; PATHOLOGY;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KINETICS; MUTATION; NEOPLASM INVASIVENESS;

EID: 84901006365     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou027     Document Type: Article

References (31)

1. Parsons DW, Jones S, Zhang XS, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897): 1807-1812.
2. Dunn GP, Andronesi OC, Cahill DP. From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurg Focus. 2013;34(2):E2.
3. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597-602.
4. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-474.
5. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-Oncol. 2009;11(4):341-347.
6. Yan H, Parsons DW, Jin GL, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
7. Kloosterhof NK, Bralten LBC, Dubbink HJ, et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. Lancet Oncol. 2011;12(1):83-91.
8. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clin Can Res. 2009;15(19):6002-6007.
9. Swanson K. Mathematical Modeling of the Growth and Control of Tumors. Seattle, WA: University of Washington; 1999.
10. Swanson K, Alvord E. Serial imaging observations and postmortem examination of an untreated glioblastoma: a traveling wave of glioma growth and invasion. Neuro-Oncol. 2002;4(4):340.
11. Swanson KR, Bridge C, Murray JD, et al. Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion. J Neurol Sci. 2003;216(1):1-10.
12. Harpold H, Alvord EJ, Swanson K. The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol. 2007;66(1):1-9.
13. Rockne R, Rockhill J, Mrugala M, et al. Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach. Phys Med Biol. 2010;55(12): 3271-3285.
14. Wang CH, Rockhill JK, Mrugala M, et al. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer Res. 2009;69(23):9133-9140.
15. Szeto MD, Chakraborty G, Hadley J, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res. 2009;69(10):4502-4509.
16. Swanson KR, Rockne RC, Claridge J, et al. Quantifying the role of angiogenesis in malignant progression of gliomas: in silico modeling integrates imaging and histology. Cancer Res. 2011; 71(24):7366-7375.
17. Basanta D1, Scott JG, Rockne R, et al. The role of IDH1 mutated tumour cells in secondary glioblastomas: an evolutionary game theoretical view. Phys Bio. 2011;8(1):015016.
18. Matlab. 7.13.0.564 (R2011b) ed. MA: The MathWorks, Inc; 2011.
19. Neal ML, Trister AD, Cloke T, et al. Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric. PLoS One. 2013;8(1):e51951.
20. Swanson KR. Quantifying glioma cell growth and invasion in vitro. Math Comput Modelling. 2008;47(5-6):638-648.
21. Swanson KR, Rostomily RC, Alvord EC. A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle. Br J Cancer. 2008; 98(1):113-119.
22. Carrillo JA, Lai A, Nghiemphu PL, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012;33(7):1349-1355.
23. Bralten LB, Kloosterhof NK, Balvers R, et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol. 2011;69(3):455-463.
24. Gozé C, Bezzina C, Gozé E, et al. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J Neurooncol. 2012;108(1):69-75.
25. Martin NK, Gaffney EA, Gatenby RA, et al. Tumour-stromal interactions in acid-mediated invasion: A mathematical model. J Theor Biol. 2010;267(3):461-470.
26. Gatenby RA, Gawlinski ET, Gmitro AF, et al. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res. 2006;66(10): 5216-5223.
27. Silva AS, Yunes JA, Gillies RJ, et al. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res. 2009;69(6):2677-2684.
28. Smallbone K, Gatenby RA, Maini PK. Mathematical modelling of tumour acidity. J Theor Biol. 2008;255(1):106-112.
29. Scott JG, Basanta D, Chinnaiyan P, et al. Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?. Neuro Oncol. 2011;13(12):1262-1264.
30. Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2012;2(31): 31ra34.
31. Beiko JL, Suki D, Hess KR, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. J Clin Oncol. 2014;16(1):81-91.